Get the Flash Player to see this player.

Unsurpassed ischemic efficacy throughout the risk spectrum in patients
undergoing Percutaneous Coronary Intervention (PCI)

Angiomax® (bivalirudin) is an anticoagulant currently approved in the U.S. for use in patients undergoing percutaneous coronary intervention, and in patients with or at risk for heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI.1

The recent Harmonizing Outcomes with Revasculation and Stents in Acute Myocardial Infarction Study (HORIZONS AMI) trial findings support the use of ANGIOMAX use in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary PCI and are consistent with those in landmark trials Randomized Evaluation of PCI Linking ANGIOMAX to Reduced Clinical Events (REPLACE-2) and Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY)* demonstrating potent efficacy and reductions in major bleeding versus heparin + glycoprotein (GP) IIb/IIIa inhibitors.1

* The safety and effectiveness of ANGIOMAX have not been established in patients with acute coronary syndromes (ACS) who are not undergoing PCI.1

Guidelines

  • ANGIOMAX with or without GP IIb/IIIa has demonstrated unsurpassed ischemic efficacy and reduced bleeding vs heparin with or without GP IIb/IIIa inhibitor in patients undergoing PCI1,5-8
  • Is supported by 7 major randomized trials1,7,8
  • Patients ranged across an increasing risk of ischemic complications5-8
  • More than 1.25 million patients have been treated with ANGIOMAX since 2001.9-11

Safety Considerations
ANGIOMAX with provisional use of glycoprotein IIb/IIIa inhibitor is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), and in patients with or at risk for heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI. ANGIOMAX is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin. ANGIOMAX is contraindicated in patients with active major bleeding or hypersensitivity to ANGIOMAX or its components. The most common (≥10%) adverse events for ANGIOMAX were back pain, pain, nausea, headache, and hypotension. An unexplained fall in blood pressure or hematocrit, or any unexplained symptom, should lead to serious consideration of a hemorrhagic event and cessation of ANGIOMAX administration. Please see complete prescribing information.

1ANGIOMAX Prescribing Information. The Medicines Company; Parsippany, NJ, December 6, 2005.

2Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: executive summary. Circulation. 2007;116:803-877.

3Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. Circulation. 2008;117:296-329.

4King SB III, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. Circulation. 2008;117:261-295.

5Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853-863.

6Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001;142:952-959.

7Stone GW, White HD, Ohman EM, et al; for the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Lancet. 2007;369:907-919.

8Stone GW, Witzenbichler B, Guagliumi G, et al, for the HORIZONS AMI trial investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218-2230.

9Data on file. The Medicines Company; Parsippany, NJ.

10Source® Non-retail Database, 2002-2007. Conshohocken, Pa: Wolters Kluwer Health.

11ACTracker® Database, 2007. Evanston, Ill: Solucient, LLC.